Pharmaceutical News

RSS

Low-dose lithium lowers involuntary motor movements in mouse model of Parkinson's disease

Low-dose lithium reduced involuntary motor movements - the troubling side effect of the medication most commonly used to treat Parkinson's disease (PD) - in a mouse model of the condition that is diagnosed in about 60,000 Americans each year. The third in a series of studies from the Andersen lab involving PD and low-dose lithium, the results add to mounting evidence that low-doses of the psychotropic drug could benefit patients suffering from the incurable, degenerative condition.

28 Jul 2015

Trends, R&D progress, and predicted revenues in RNAi therapies

When will RNAi therapies reach the market? Visiongain's brand new report shows you potential revenues to 2025, assessing data, trends, opportunities and prospects there.

25 Jul 2015

CU-Boulder study reveals how and when placebo effect works

You don't think you're hungry, then a friend mentions how hungry he is or you smell some freshly baked pizza and whoaaa, you suddenly feel really hungry. Or, you've had surgery and need a bit of morphine for pain. As soon as you hit that button you feel relief even though the medicine hasn't even hit your bloodstream.

25 Jul 2015

CHMP recommends Zalviso for management of acute post-operative pain in adult patients

AcelRx Pharmaceuticals, Inc. announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency, has adopted a positive opinion for Zalviso (sufentanil sublingual tablets).

25 Jul 2015

Novartis announces FDA approval of Odomzo (sonidegib) 200 mg capsules for treatment of laBCC patients

Novartis today announced the US Food and Drug Administration has approved Odomzo (sonidegib, formerly LDE225) 200 mg capsules for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.

25 Jul 2015

FDA approves Praluent (alirocumab) Injection for treatment of patients with high LDL cholesterol

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the U.S. Food and Drug Administration approved Praluent (alirocumab) Injection, the first FDA-approved treatment in a new class of drugs known as PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors.

25 Jul 2015

EMA's CHMP recommends approval of Praluent (alirocumab) for use in patients with hypercholesterolemia

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the European Medicine Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion for the marketing authorization of Praluent (alirocumab), recommending its approval for use in certain adult patients with hypercholesterolemia.

24 Jul 2015

New computer algorithm helps scientists see drug's activity inside the body

Researchers at Columbia University Medical Center have developed a computer algorithm that is helping scientists see how drugs produce pharmacological effects inside the body. The study, published in the journal Cell, could help researchers create drugs that are more efficient and less prone to side effects, suggest ways to regulate a drug's activity, and identify novel therapeutic uses for new and existing compounds.

24 Jul 2015

Aggressive vaccination effort reduces transmission of measles among North American Amish communities

An aggressive vaccination effort in response to the 2014 measles outbreak among North American Amish communities in Ohio significantly reduced the transmission of measles and the expected number of cases, according to a new study, even though under-vaccination among the North American Amish and in other communities around the United States led to the highest national annual number of reported cases in 2014 in the last 20 years.

24 Jul 2015

TSRI awarded two grants to support development of effective vaccine against HIV/AIDS

The Scripps Research Institute has been awarded two grants from the Bill & Melinda Gates Foundation totaling more than $4.5 million to fund efforts to develop a vaccine against HIV/AIDS.

24 Jul 2015

Teens using marijuana for medical reasons more likely to become addicted to it

A new University of Michigan study finds that teens using marijuana for medical reasons are 10 times more likely to say they are hooked on marijuana than youth who get marijuana illegally.

24 Jul 2015

MSU scientists suggest that common glaucoma medication could be used to treat TB

A new discovery by Michigan State University scientists suggests that a common medication used to treat glaucoma could also be used to treat tuberculosis, even the drug-resistant kind.

24 Jul 2015

New Penn study finds link between graduate medical training and brand name statin prescribing

Physicians in training are twice as likely to order a costly brand-name statin (used to lower blood cholesterol levels) when supervised by senior physicians who prefer those medications in their own practice, according to a new study led by researchers at the Perelman School of Medicine at the University of Pennsylvania and published online in the Journal of General Internal Medicine.

24 Jul 2015

Amgen announces submission of supplemental New Drug Application to FDA for Kyprolis (carfilzomib)

Amgen today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Kyprolis (carfilzomib) for Injection to seek an expanded indication for the treatment of patients with a form of blood cancer, relapsed multiple myeloma, who have received at least one prior therapy.

23 Jul 2015

PharmaMar, TTY Biopharm sign agreement to market and distribute APLIDIN (plitidepsin) in Taiwan

PharmaMar has entered into an exclusive license and commercialization agreement with the pharmaceutical company TTY Biopharm to market and distribute the drug candidate APLIDIN (plitidepsin) in Taiwan. Under the terms of the agreement, PharmaMar will receive an upfront payment, royalties and additional remunerations for regulatory milestones achieved by APLIDIN (plitidepsin).

23 Jul 2015

Omeros' OMS721 granted FDA Fast Track designation for treatment of atypical hemolytic uremic syndrome

Omeros Corporation today announced that the U.S. Food and Drug Administration granted Fast Track designation to OMS721 for the treatment of patients with atypical hemolytic uremic syndrome (aHUS). OMS721 is the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system.

23 Jul 2015

New drug shows promise in slowing Alzheimer’s disease

New research findings have fuelled hopes of a drug that can slow down the progression of Alzheimer’s disease.

23 Jul 2015

Two new studies link Xarelto to stomach bleeds and eye hemorrhaging

MT Services LLC, a Lawsuit Settlement News Reporting Company which operates lawsuitsettlementnews.com, announced today that two new studies have shown a link between Xarelto and stomach bleeds and eye hemorrhaging.

23 Jul 2015

UC San Diego researchers receive NIH grant to test efficacy of Sanofi's pain drug in treating Chagas disease

The National Center for Advancing Translational Sciences, part of the National Institutes of Health (NIH), has awarded James McKerrow, MD, PhD, director of the University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, with a 2015 New Therapeutic Uses Award.

23 Jul 2015

Researchers discover experimental drug that treats hot flashes, other menopausal symptoms without side effects

Researchers have discovered an experimental medication that treats hot flashes and other menopausal symptoms without the life-threatening risks of hormone replacement therapy, according to a team led by a UNT Health Science Center scientist.

23 Jul 2015

Pharmaceutical News

Low-dose lithium lowers involuntary motor movements in mouse model of Parkinson's disease

Trends, R&D progress, and predicted revenues in RNAi therapies

CU-Boulder study reveals how and when placebo effect works

CHMP recommends Zalviso for management of acute post-operative pain in adult patients

Novartis announces FDA approval of Odomzo (sonidegib) 200 mg capsules for treatment of laBCC patients

FDA approves Praluent (alirocumab) Injection for treatment of patients with high LDL cholesterol

EMA's CHMP recommends approval of Praluent (alirocumab) for use in patients with hypercholesterolemia

New computer algorithm helps scientists see drug's activity inside the body

Aggressive vaccination effort reduces transmission of measles among North American Amish communities

TSRI awarded two grants to support development of effective vaccine against HIV/AIDS

Teens using marijuana for medical reasons more likely to become addicted to it

MSU scientists suggest that common glaucoma medication could be used to treat TB

New Penn study finds link between graduate medical training and brand name statin prescribing

Amgen announces submission of supplemental New Drug Application to FDA for Kyprolis (carfilzomib)

PharmaMar, TTY Biopharm sign agreement to market and distribute APLIDIN (plitidepsin) in Taiwan

Omeros' OMS721 granted FDA Fast Track designation for treatment of atypical hemolytic uremic syndrome

New drug shows promise in slowing Alzheimer’s disease

Two new studies link Xarelto to stomach bleeds and eye hemorrhaging

UC San Diego researchers receive NIH grant to test efficacy of Sanofi's pain drug in treating Chagas disease

Researchers discover experimental drug that treats hot flashes, other menopausal symptoms without side effects

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News